China Approves Rocbrutinib, a Dual-Mode BTK Inhibitor, for Drug-Resistant Lymphoma
Key Insights
China's NMPA granted marketing approval to rocbrutinib, an oral BTK (search) inhibitor developed by Lupeng Pharmaceutical (search), for lymphoma (search) patients who have developed resistance to prior therapies.
The drug employs a dual binding mechanism: irreversible binding to normal BTK (search) and continued inhibition of BTK harboring multiple resistance-associated mutations.
Phase II trial results demonstrated an objective response rate of 63.9%, a complete response rate of 23%, and a median duration of response of 16.5 months.
China's National Medical Products Administration (NMPA) approved rocbrutinib, a novel oral targeted therapy, on Thursday, offering a new treatment avenue for lymphoma (search) patients who have exhausted other options due to drug resistance. Developed by Guangzhou-based Lupeng Pharmaceutical (search), the drug represents a significant advance in addressing one of the most persistent challenges in oncology: cancer's ability to evade targeted therapies through mutation.
Rocbrutinib received marketing authorization following its inclusion in the NMPA's Breakthrough Therapy Designation (BTD) list, a regulatory pathway designed to expedite the development of drugs addressing serious conditions with unmet medical need.
Dual-mode mechanism targets resistance at its source
Rocbrutinib is designed to bind to and inhibit Bruton's tyrosine kinase (BTK (search)), a protein that serves as a critical survival switch in cancer cells. What distinguishes rocbrutinib from conventional BTK inhibitors is its dual-mode binding capability.
On one hand, the drug binds firmly to the normal BTK (search) target in an irreversible manner, blocking the downstream signaling that drives malignant B-cell proliferation. On the other hand, even when BTK has undergone multiple resistance-related mutations — a common cause of treatment failure with earlier-generation BTK inhibitors — rocbrutinib can still bind to and inhibit the altered protein. This dual mechanism allows the drug to remain effective for patients who have developed resistance to prior treatments.
By blocking the survival switch of cancer cells through these two distinct modes, rocbrutinib induces cancer cell death, offering a mechanistically differentiated approach in the BTK (search) inhibitor class.
Phase II data demonstrate meaningful clinical benefit
The approval was supported by results from a Phase II clinical trial, which enrolled lymphoma (search) patients who had become resistant to other drugs and had few remaining treatment options. The data showed an objective response rate (ORR) of 63.9%, meaning approximately 64 out of every 100 patients experienced significant tumor shrinkage. A complete response rate of 23% was observed, indicating that 23 out of every 100 patients had complete tumor disappearance on imaging.
The median duration of response reached 16.5 months, with approximately half of responders maintaining clinical benefit beyond this time point. These outcomes are particularly noteworthy given the heavily pre-treated, drug-resistant population studied.
Addressing an unmet need in lymphoma (search)
The approval is expected to offer a new option for lymphoma (search) patients who have developed resistance to earlier treatments and face a scarcity of effective therapeutic alternatives. Resistance to BTK (search) inhibitors has been a growing clinical concern, as mutations in the BTK binding site can render first- and second-generation agents ineffective over time. Rocbrutinib's ability to maintain inhibitory activity against mutated BTK directly addresses this gap.
China's accelerating innovative drug landscape
Rocbrutinib's approval contributes to a record-setting year for pharmaceutical innovation in China. In 2025, a total of 76 innovative drugs received approval from the NMPA, marking a new high for the country's drug regulatory system and reflecting the growing output of China's biopharmaceutical research and development sector.